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Therefore,	 the	 objective	 of	 this	 research	 was	 to	 characterize	 the	 prevalence	 of	 cigarette	 smoking,	 alcohol	 consumption,	 non-prescribed	 cannabis	 use,	 and	 illicit	 drug	 use	 from	 the	 Canadian	 HIV	 Women’s	 Sexual	 and
















































































	16-–35	(years) 145 10.2	(8.7,	11.9) 8,749 21.1	(20.6,	21.7) 10.2e
	36-–45 162 11.4	(9.8,	13.2) 4,582 11.2	(10.6,	11.5) 11.4
	46-–55 178 12.5	(10.9,	14.3) 5,775 13.9	(13.4,	14.5) 12.5
	>	55 99 7.0	(5.7,	8.4) 12,020 29.0	(28.5,	29.6) 7.0
Black
	16-351077.5	(6.3,	9.0)4571.1	(0.9,	1.3)7.5	36-–35 107 7.5	(6.3,	9.0) 457 1.1	(0.9,	1.3) 7.5
	36–45 163 11.5	(9.9,	13.2) 280 0.7	(0.5,	0.9) 11.5
	46-–55 111 7.8	(6.5,	9.3) 333 0.8	(0.6,	1.1) 7.8
	>	55 37 2.6	(1.9,	3.6) 268 0.7	(0.5,	0.8) 2.6
Indigenous
	16-–35 100 7.0	(5.8,	8.5) 424 1.0	(0.9,	1.2) 7.0
	36-–55 120 8.4	(7.1,	10.0) 161 0.4	(0.3,	0.5) 8.4
	36-–45 74 5.2	(4.2,	6.5) 176 0.4	(0.3,	0.5) 5.2
	46-–55 24 1.7	(1.1,	2.5) 255 0.6	(0.5,	0.7) 1.7
Others
16-	16–35 20 1.4	(0.9,	2.2) 3,286 7.9	(7.4,	8.4) 1.4
	36-–45 34 2.4	(1.7,	3.3) 1,837 4.4	(4.0,	4.9) 2.4
	46-–55 37 2.6	(1.9,	3.6) 1,271 3.1	(2.7,	3.5) 2.6
	>	55 11 0.8	(0.4,	1.4) 1,539 3.7	(3.4,	4.1) 0.8
Relationship	status
	Single 689 48.7	(46.1,	51.3) 10,438 24.3	(23.7,	24.8) 26.6	(24.6,	28.7)
	Married,	common-law 545 32.1	(29.7,	34.6) 24,971 58.0	(57.3,	58.7) 55.3	(52.7,	57.9)
	Separated/divorced/widowed 271 19.2	(17.2,	21.3) 7,636 17.7	(17.2,	18.3) 18.1	(15.8,	20.4)
Education	status
	Less	than	high	school 227 16.1	(14.2,	18.1) 6,568 15.4	(14.9,	16.0) 12.3	(11.0,	13.6)
	High	school	completed 532 37.6	(35.1,	40.2) 10,514 24.7	(24.0,	25.4) 23.9	(21.9,	25.9)
	Diploma/trade/college 456 32.2	(29.8,	34.7) 12,998 30.6	(29.8,	31.3) 35.9	(33.4,	38.4)
	University	degree	(≥Bachelor’s	degree) 200 14.1	(12.4,	16.1) 12,474 29.3	(28.6,	30.1) 27.9	(25.4,	30.4)
Yearly	personal	incomeb
	<20,000	CADc 997 70.3	(67.8,	72.6) 12,263 29.1	(28.4,	29.9) 28.1	(26.1,	30.0)
	20,000	to	<40,000	CAD 244 17.2	(15.3,	19.3) 10,425 24.8	(24.1,	25.5) 24.5	(22.4,	26.7)
	≥	40,000	CAD 144 10.1	(8.7,	11.8) 12,620 30.0	(29.2,	30.8) 33.1	(30.4,	35.8)
	Not	stated 34 2.4	(1.7,	3.3) 6,795 16.1	(15.5,	16.8) 14.3	(12.3,	16.3)










































































































































































































































































































could	 in	 part	 be	 because	 of	 other	 uncontrolled	 population	 background	 characteristics.	 For	 example,	 prior	 studies	 have	 highlighted	 the	 contribution	 of	 socioeconomic	 factors	 (e.g.,	 low	 income,	 unemployment)	 and	mental	 health
conditions	to	substance	among	WLWH	(Cook	et	al.,	2009).	Moreover,	HIV-specific	factors	such	as	HIV-related	stigma	may	play	a	role	in	substance	use	as	a	maladaptive	or	avoidant	coping	strategy	(Turan	et	al.,	2017).	However,	control
of	 these	 in	cross-sectional	analysis	 can	be	problematic	 in	 ignoring	potential	mediation	and	creating	artificially	 similar	groups	 that	obscure	 real	differences	 that	 can	 result	 from	age	 (or	 life	 stage)	and	systemic	discrimination	and
differential	life	options	across	ethnoracial	groups.
Our	findings	were	consistent	with	the	findings	of	the	few	available	studies	comparing	WLWH	with	HIV-negative	women.	A	higher	proportion	of	cigarette	smoking	was	found	among	WLWH	in	a	2015	US	study	(34.6%	vs.	18.0%
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Highlights
• Women	with	HIV	(WLWH)	were	26.8%	excess	daily	smokers	vs.	general	population	women.
• WLWH	were	8.0%	excess	regular	cannabis	users	vs.	general	population	women.
• WLWH	were	16.7%	excess	regular	crack/cocaine	users	vs.	general	population	women.
Queries	and	Answers
Query:	Please	check	the	presentation	of	‘Tables	1-4’,	and	correct	if	necessary.
Answer:	The	presentation	of	the	tables	is	correct
Query:	Your	article	is	registered	as	a	regular	item	and	is	being	processed	for	inclusion	in	a	regular	issue	of	the	journal.	If	this	is	NOT	correct	and	your	article	belongs	to	a	Special	Issue/Collection	please
contact	s.hubbard@elsevier.com	immediately	prior	to	returning	your	corrections.
Answer:	Correct,	this	article	is	registered	as	a	regular	item	and	regular	issue	of	the	journal.	
Query:	The	author	names	have	been	tagged	as	given	names	and	surnames	(surnames	are	highlighted	in	teal	color).	Please	confirm	if	they	have	been	identified	correctly.
Answer:	Yes
Query:	Please	note	that	the	significance	of	footnote	’#’	link	to	the	’On	Behalf	of	the	CHIWOS	Research	Team’	has	not	been	provided.	Therefore	it	has	been	removed.	Please	check	and	correct	if
necessary.
Answer:	Please	see	the	attached	file.	We	provided	(in	the	initial	submission)	the	list	of	the	names	of	our	survey	research	team.	The	sign	"#"	refers	to	the	list	that	is	now	attached.	
Attachments:	CHIWOS	research	team.docx
Query:	Please	check	the	presentation	of	all	affiliations,	and	correct	if	necessary.
Answer:	They	are	correct.	
Query:	One	or	more	sponsor	names	and	the	sponsor	country	identifier	may	have	been	edited	to	a	standard	format	that	enables	better	searching	and	identification	of	your	article.	Please	check	and
correct	if	necessary.
Answer:	Yes
Query:	Uncited	reference:	This	section	comprises	reference	that	occur	in	the	reference	list	but	not	in	the	body	of	the	text.	Please	position	the	reference	in	the	text	or,	alternatively,	delete	it.	Any
reference	not	dealt	with	will	be	retained	in	this	section.
Answer:	This	reference	refers	to	this	section	of	the	introduction	(first	paragraph	in	the	Introduction):	"...	despite	the	substantial	advances	obtained	from	combination	antiretroviral	therapy	(cART),	e.g.,
improved	life	expectancy	in	PLWH	(2008)."	We	only	have	the	"2008"	in	the	body	of	the	text	not	the	list	of	the	authors	of	this	reference.	The	reason	is	that	there	is	no	list	of	co-authors	for	this
publication/reference.	The	suggestion	is	this:	A)	Please	add	this	"Antiretroviral	Therapy	Cohort	Collaboration"	to	the	first	paragraph	of	the	Introduction	in	the	corresponding	section	(specified)	and
change	it	as,	"...	despite	the	substantial	advances	obtained	from	combination	antiretroviral	therapy	(cART),	e.g.,	improved	life	expectancy	in	PLWH	(Antiretroviral	Therapy	Cohort	Collaboration,
2008)."	Then,	B)	please	revise	this	reference	in	the	reference	list	as,	Antiretroviral	Therapy	Cohort	Collaboration,	2008.	Life	expectancy	of	individuals	on	combination	antiretroviral	therapy	in	high-
income	countries:	a	collaborative	analysis	of	14	cohort	studies.	Lancet	372,	293-299.
• WLWH	were	11.2%	excess	regular	heroin	users	vs.	general	population	women.
• Alcohol	use	was	either	similar	or	lower	in	WLWH	vs.	general	population	women.
